These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
116 related items for PubMed ID: 2511378
1. L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients. Yoshida M, Noguchi S, Kuramoto S. Kurume Med J; 1989; 36(2):67-74. PubMed ID: 2511378 [Abstract] [Full Text] [Related]
2. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease. Ogawa N, Yamamoto M, Takayama H. J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472 [Abstract] [Full Text] [Related]
3. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia]. Kondo T. Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393 [No Abstract] [Full Text] [Related]
4. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness. Birkmayer W, Birkmayer G, Lechner H, Riederer P. J Neural Transm; 1983 Mar; 58(3-4):305-13. PubMed ID: 6420517 [Abstract] [Full Text] [Related]
5. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease. Yamamoto M, Ogawa N, Ujike H. J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714 [Abstract] [Full Text] [Related]
6. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine. Ogawa N, Kuroda H, Yamamoto M, Nukina I, Ota Z. Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755 [Abstract] [Full Text] [Related]
7. Effect of L-threo-3,4-dihydroxyphenylserine on regional cerebral blood flow in patients with Parkinson's disease. Ujike H, Yamamoto M. J Neurol Sci; 1988 Jan; 83(1):75-80. PubMed ID: 3126272 [Abstract] [Full Text] [Related]
11. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. Tohgi H, Abe T, Takahashi S. J Neural Transm Park Dis Dement Sect; 1993 Jan; 5(1):27-34. PubMed ID: 8439390 [Abstract] [Full Text] [Related]
14. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Tohgi H, Abe T, Takahashi S, Takahashi J, Ueno M, Nozaki Y. Neurosci Lett; 1990 Aug 14; 116(1-2):194-7. PubMed ID: 2259448 [Abstract] [Full Text] [Related]
15. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease. Teelken AW, van den Berg GA, Muskiet FA, Staal-Schreinemachers AL, Wolthers BG, Lakke JP. J Neural Transm Park Dis Dement Sect; 1989 Aug 14; 1(3):177-88. PubMed ID: 2476157 [Abstract] [Full Text] [Related]
16. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. Suzuki T, Sakoda S, Ueji M, Kishimoto S, Hayashi A, Kondo T, Narabayashi H. Neurology; 1984 Nov 14; 34(11):1446-50. PubMed ID: 6436731 [Abstract] [Full Text] [Related]
17. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Iida N, Koshikawa S, Akizawa T, Tsubakihara Y, Marumo F, Akiba T, Kawaguchi Y, Imada A, Yamazaki C, Suzuki M. Am J Nephrol; 2002 Nov 14; 22(4):338-46. PubMed ID: 12169865 [Abstract] [Full Text] [Related]
18. [Pure akinesia presenting with antecollis]. Ota S, Tsuchiya K. No To Shinkei; 2005 Oct 14; 57(10):893-8. PubMed ID: 16277235 [Abstract] [Full Text] [Related]